Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Common Equity: 2016-2024

Historic Common Equity for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$49.2 million.

  • Akebia Therapeutics' Common Equity rose 182.52% to $41.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 182.52%. This contributed to the annual value of -$49.2 million for FY2024, which is 60.82% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Common Equity of -$49.2 million as of FY2024, which was down 60.82% from -$30.6 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Common Equity registered a high of $244.4 million during FY2020, and its lowest value of -$49.2 million during FY2024.
  • Its 3-year average for Common Equity is -$24.8 million, with a median of -$30.6 million in 2023.
  • In the last 5 years, Akebia Therapeutics' Common Equity skyrocketed by 38.10% in 2020 and then tumbled by 684.78% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Common Equity (MRY) stood at $244.4 million in 2020, then plummeted by 69.71% to $74.0 million in 2021, then plummeted by 92.93% to $5.2 million in 2022, then tumbled by 684.78% to -$30.6 million in 2023, then plummeted by 60.82% to -$49.2 million in 2024.
  • Its Common Equity was -$49.2 million in FY2024, compared to -$30.6 million in FY2023 and $5.2 million in FY2022.